-
-
-
[1] CHANAN-KHAN A A,GIRALT S.Importance of achieving a complete response in multiple myeloma,and the impactof novel agents[J].J Clin Oncol,2010,28:2612-2624.
[2] BLADE J,DE LARREA C F.Toward deeper response in MM[J].Blood,2011,117:2986-2987.
[3] JAGANNATH S.Treatment paradigm for Multiple Myeloma:"Pro Chronification"[M].3rd.German:Heidelberg Myeloma Workshop,2011:79-80.
[4] KUMAR S K,MIKHAEL J R,BUADI F K,et al.Management of newly diagnosed symptomatic multiple myeloma:updated MayoStratification of Myeloma and Risk-Adapted Therapy(mSMART)consensus guidelines[J].Mayo Clin Proc,2009,84:1095-1110.
[5] MORGAN G J,GREGORY W M,DAVIES F E,et al.The role of maintenance thalidomide therapy in multiple myeloma:MRC Myeloma IX results and meta-analysis[J].Blood,2012,119:7-15.
[6] LUDWIG H,DURIE B G,MCCARTHY P,et al.IMWG consensus on maintenance therapy in multiple myeloma[J].Blood,2012,119:3003-3015.
[7] ALEXANIAN R,GEHAN E,HAUT A,et al.Unmaintained remissions in multiple myeloma[J].Blood,1978,51:1005-1011.
[8] BELCH A,SHELLEY W,BERGSAGEL D,et al.A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients[J].Br J Cancer,1988,57:94-99.
[9] Myeloma Trialists' Collaborative Group.Interferon as therapy for multiple myeloma:an individual patient data overviewof 24 randomized trials and 4012 patients[J].Br J Haematol,2001,113:1020-1034.
[10] FRITZ E,LUDWIG H.Interferon-alpha treatment in multiple myeloma:meta-analysis of 30 randomisedtrials among 3948 patients[J].Ann Oncol,2000,11:1427-1436.
[11] ALEXANIAN R,WEBER D,DIMOPOULOS M,et al.Randomized trial of alpha-interferon or dexamethasone as maintenance treatmentfor multiple myeloma[J].Am J Hematol,2000,65:204-209.
[12] MORGAN G J,GREGORY W M,DAVIES F E,et al.The role of maintenance thalidomide therapy in multiple myeloma:MRC Myeloma IX results and meta-analysis[J].Blood,2012,119:7-15.
[13] ATTAL M,HAROUSSEAU J L,LEYVRAZ S,et al.Maintenance therapy with thalidomide improves survival in patients with multiple myeloma[J].Blood,2006,108:3289-3294.
[14] BARLOGIE B,TRICOT G,ANAISSIE E,et al.Thalidomide and hematopoietic-cell transplantation for multiple myeloma[J].N Engl J Med,2006,354:1021-1030.
[15] BARLOGIE B,ATTAL M,CROWLEY J,et al.Long-term follow-up of autotransplantation trials for multiple myeloma:update ofprotocols conducted by the intergroupe francophone du myelome,southwest oncologygroup,and university of Arkansas for medical sciences[J].J Clin Oncol,2010,28:1209-1214.
[16] DIPERSIO J F,MICALLEF I N,STIFF P J,et al.Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization andtransplantation for patients with non-Hodgkin's lymphoma[J].J Clin Oncol,2009,27:4767-4773.
[17] SPENCER A,PRINCE H M,ROBERTS A W,et al.Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure[J].J Clin Oncol,2009,27:1788-1793.
[18] BEKSAC M,HAZNEDAR R,FIRATLI-TUGLULAR T,et al.Addition of thalidomide to oral melphalan/prednisone in patients with multiplemyeloma not eligible for transplantation:results of a randomized trial from the Turkish Myeloma Study Group[J].Eur J Haematol,2011,86:16-22.
[19] SACCHI S,MARCHESELLI R,LAZZARO A,et al.A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant[J].Leuk Lymphoma,2011,52:1942-1948.
[20] SCOTT E,REECE D.What is the benefit of maintenance therapy with lenalidomide or bortezomib after autologous stem cell transplantation in multiple myeloma and what is the risk of developing a secondary primary malignancy[J].Hematol Am Soc Hematol Educ Program,2011,2011:205-207.
[21] DIMOPOULOS M A,CHEN C,SPENCER A,et al.Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractorymultiple myeloma[J].Leukemia,2009,23:2147-2152.
[22] MAHINDRA A,LAUBACH J,RAJE N,et al.Latest advances and current challenges in the treatment of multiple myeloma[J].Nat Rev Clin Oncol,2012,9:135-143.
[23] RICHARDSON P G,WELLER E,LONIAL S,et al.Lenalidomide,bortezomib,and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma[J].Blood,2010,116:679-686.
-
计量
- 文章访问数: 166
- PDF下载数: 131
- 施引文献: 0
下载: